Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0ACJDV
ADC Name
Anti-CD19(LC)-G7VIM-2i
Synonyms
Anti-CD19(LC)-G7VIM 2i
   Click to Show/Hide
Organization
LegoChem Biosciences, Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Burkitt lymphoma [ICD11:2A85]
Investigative
Drug-to-Antibody Ratio
2
Structure
Antibody Name
DI-B4-(LC)-GGGGGGG-CVIM
  Antibody Info 
Antigen Name
B-lymphocyte antigen CD19 (CD19)
  Antigen Info 
Payload Name
Monomethyl auristatin F
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Anti-CD19(LC)-G7VIM-2i linker
Conjugate Type
Site-specific conjugation through the CaaX sequence at the C-terminal.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
110
ng/mL
Raji cells
EBV-related Burkitt lymphoma
Half Maximal Inhibitory Concentration (IC50) 
> 10
ug/mL
K562 cells
Chronic myeloid leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 110 ng/mL Positive CD19 expression (CD19 +++/++)
Method Description
Raji cells were seeded in a 96-wellplate at 200,000 cells/well in 100 pL of growth media. The cells were incubated at 37°C in 5% CO2, for 1 day. Serial dilutions of anti-CD19 ADC from 4.0 ug/mL to 1.5625 ng/mL in 100 pL media were added tothe wells, and the cells were incubated with the antibodies for 72 hours.
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 10.00 ug/mL Negative CD19 expression (CD19 -)
Method Description
K562 cells were seeded in a 96-wellplate at 200,000 cells/well in 100 pL of growth media. The cells were incubated at 37°Cin 5% CO2, for 1 day. Serial dilutions of anti-CD19 ADC from 4.0 ug/mL to 1.5625 ng/mL in 100 pL media were added tothe wells, and the cells were incubated with the antibodies for 72 hours.
In Vitro Model Chronic myeloid leukemia K562 cells CVCL_0004
References
Ref 1 Compositions and methods related to anti-cd19 antibody drug conjugates; 2017-03-30.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.